17:03 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....
12:02 , Oct 22, 2018 |  BC Extra  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Photofrin porfimer sodium: SPA received

Pinnacle received an SPA from FDA for a Phase III trial to evaluate Photofrin to treat unresectable advanced perihilar cholangiocarcinoma Bismuth type III/IV. The company expects to begin the trial this half. Photofrin is marketed...
02:08 , Jan 9, 2014 |  BC Extra  |  Top Story

Forest to acquire Aptalis

Forest Laboratories Inc. (NYSE:FRX) jumped $10.54 (18%) to $69.30 on Wednesday after announcing it will acquire gastrointestinal company Aptalis Holdings Inc. (Bridgewater, N.J.) for $2.9 billion in cash. The move translates to a $2.8 billion...
01:06 , Dec 27, 2013 |  BC Extra  |  Top Story

Aptalis files for $500 million IPO

Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat...
01:10 , Oct 25, 2013 |  BC Extra  |  Financial News

Aptalis rumored to be planning IPO after lack of bidder

Gastrointestinal company Aptalis Pharma Inc. (Mont-Saint-Hilaire, Quebec) could not be reached for comment on rumors that the company hired Goldman Sachs and JPMorgan and is planning an IPO slated for next year. According to Reuters,...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Photofrin porfimer sodium: Phase I started

Researchers at Medical College of Wisconsin (MCW) and Children's Hospital of Wisconsin began an open-label, dose-escalation, U.S. Phase I trial to evaluate 0.5, 1.3, 2 and 3 mg/kg IV Photofrin 24 hours prior to PDT...
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Maple leaf windfall

The $510.3 million Gilead Sciences Inc. will pay to take out YM BioSciences Inc. puts the deal in the top five transactions involving a Canadian biopharma company in the past five years. Gilead (NASDAQ:GILD) will...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Photofrin porfimer sodium regulatory update

Pinnacle submitted regulatory applications to Germany's Federal Institute for Drugs and Medical Devices and France's National Agency for the Safety of Medicine and Health Products for Photofrin porfimer sodium to treat unresectable advanced hilar cholangiocarcinoma....